By Kevin E. Noonan –In many corners, Supreme Court Chief Justice John Roberts has come under criticism, justified or not, over the performance of the Court in the second Trump Administration. Last week, the Chief took steps that should be
By Kevin E. Noonan –On August 25th, the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office designated as Informative its decision in Ex parte Chowdhury, directed toward what constituted improper Markush groupings (see Ex parte
By Kevin E. Noonan –Measurement of the hydrogen ion concentration in an aqueous solution is represented (on a logarithmic scale) as the pH, wherein water under ambient conditions (a temperature of 25°C) has a neutral pH of 7 and the
By Kevin E. Noonan –Written description jurisprudence has been one of the areas of statutory explication of Section 112(a) (along with enablement) primarily under the purview of the Federal Circuit (until the Supreme Court’s Amgen v. Sanofi decision on enablement;
By Kevin E. Noonan –In addition to Arbutus Biopharma and Genevant Sciences defending on appeal the District Court’s summary judgment decision in their favor, these plaintiffs filed their complaint against the Federal Government pursuant to 28 U.S.C. § 1498 for
By Kevin E. Noonan –The parties in the appeal of the District Court’s grant of summary judgment to Arbutus and Genevant over Moderna, holding Moderna liable for $1.3 billion in patent infringement damages, attracted a fair amount of amicus support.
By Kevin E. Noonan –The parties in the appeal of the District Court’s grant of summary judgment to Arbutus and Genevant over Moderna, holding Moderna liable for $1.3 billion in patent infringement damages attracted a fair amount of amicus support.
By Kevin E. Noonan –Arbutus Biopharma and Genevant Sciences, having prevailed in district court litigation against Moderna involving infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 regarding lipid nanoparticle (LNP) technology
By Kevin E. Noonan –One of the beneficial characteristics of the response to the COVID-19 pandemic were pledges from companies involved in developing vaccines (such as Moderna, Pfizer, BioNTech, and others) not to enforce patents on relevant technology during the
By Donald Zuhn –In a Patent Alert distributed last week, the U.S. Patent and Trademark Office reminded stakeholders that beginning on Monday, July 20, patent applicants and owners who are not domiciled in the U.S. or its territories are now
